Conventional bioassays take advantage of the antiviral activity of type I IFN to measure the inhibition of virus-induced cytopathic effects in cell culture [14] . In this study, we presented an improved bioassay by employing a recombinant VSV replicon equipped with two reporter proteins. This assay proved to be advantageous over the conventional assay with respect to biosafety, sensitivity, and time requirements.